We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

95 hedge funds and large institutions have $227M invested in Aclaris Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

3.67% less ownership

Funds ownership: 95.46% → 91.79% (-3.7%)

4% less funds holding

Funds holding: 99 → 95 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

21% less capital invested

Capital invested by funds: $289M → $227M (-$61.5M)

76% less call options, than puts

Call options by funds: $68K | Put options by funds: $288K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
-4
Holders Change %
-4.04%
% of All Funds
2.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
15
Increased
36
Reduced
25
Closed
19
Calls
$68K
Puts
$288K
Net Calls
-$220K
Net Calls Change
-$336K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.4M
2
ECM
Endurant Capital Management
California
+$3.62M
3
Man Group
Man Group
United Kingdom
+$3.44M
4
RSCM
Rock Springs Capital Management
Maryland
+$2.46M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.6M
2
FCMI
Foresite Capital Management IV
California
-$5.53M
3
EC
EcoR1 Capital
California
-$4.54M
4
UBS Group
UBS Group
Switzerland
-$4.2M
5
BlackRock
BlackRock
New York
-$3.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCAMU
101
Rothschild & Co Asset Management US
Connecticut
– -$621K -84,047 Closed
CC
102
Caxton Corporation
New Jersey
– -$453K -61,264 Closed
RSS
103
Rosenblum Silverman Sutton
California
– -$429K -58,110 Closed
AG
104
Aperio Group
California
– -$179K -24,200 Closed
EAM
105
Erste Asset Management
Austria
– -$140K -20,000 Closed
SIM
106
Spark Investment Management
New York
– -$141K -19,200 Closed
PA
107
Profund Advisors
Maryland
– -$109K -14,711 Closed
MIM
108
MetLife Investment Management
New Jersey
– -$97.2K -13,157 Closed
Tudor Investment Corp
109
Tudor Investment Corp
Connecticut
– -$95K -12,906 Closed
SCA
110
Secor Capital Advisors
New York
– -$95K -12,860 Closed
MLICM
111
Metropolitan Life Insurance Company (MetLife)
New York
– -$89.3K -12,078 Closed
Los Angeles Capital Management
112
Los Angeles Capital Management
California
– -$83K -11,215 Closed
LTFS
113
Ladenburg Thalmann Financial Services
Florida
– -$7 -1 -4%
1 2 3 4
5

ACRS Hedge Fund Activity: Q1 2019 in Review

95 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2019, worth a combined $227M — down 21% from $289M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ACRS and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 36 added.

The largest buyer was Vanguard Group, adding an estimated $7.4M. The largest seller was Fidelity Investments, cutting an estimated $6.6M.

  • 95 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2019, down from 99 in Q4 2018.
  • Funds reported $227M of Aclaris Therapeutics stock for Q1 2019, down 21% quarter-over-quarter.
  • 15 funds opened new Aclaris Therapeutics positions in Q1 2019 and 19 closed out, a net change of -4 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $7.4M added.
  • The largest Aclaris Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $6.6M sold.

Based on aggregated 13F filings for Q1 2019.